The significance of the figures lies in the scale of private philanthropy in neurological research, where public funding is often modest relative to the burden of disease.
The Michael J. Fox Foundation for Parkinson's Research raised a reported record $6 million at its annual gala in New York on November 14, according to USA TODAY. The event, titled 'A Funny Thing Happened on the Way to Cure Parkinson's', was held at the Waldorf Astoria and brought together entertainers, supporters and members of the Fox family.
The foundation's own website states that it has directed more than $2.5 billion towards Parkinson's research in its first 25 years. Founded in 2000, the organisation describes itself as the world's largest nonprofit funder of Parkinson's research. It says treatment options have increased by 200 per cent since its launch and that nearly two dozen treatments have been approved over the past decade, and it aims to fund $600 million in research for 2026.
Fox was diagnosed with young-onset Parkinson's disease in 1991, at the age of 29, and disclosed the diagnosis publicly in 1998. He established the foundation two years later. The actor, now 65, attended the gala with his wife, Tracy Pollan, and their three daughters, Esmé, 25, and twins Aquinnah and Schuyler, 31. The couple's son, Sam, 37, was not present. The family rarely appears together in public, and the gathering drew attention for that reason as much as for the fundraising.
The evening featured musical performances by John Mayer and Brad Paisley, comedy appearances and hosting by Denis Leary, according to the report. Tom Dumont, the No Doubt guitarist who publicly shared his own early-onset Parkinson's diagnosis earlier in 2026, took part in a performance with Fox, Mayer and members of Super Soul Banned. Pollan told PEOPLE at the event that the money raised goes towards supporting scientists and their work.
The significance of the figures lies in the scale of private philanthropy in neurological research, where public funding is often modest relative to the burden of disease. A single charity directing billions over a quarter-century is unusual, and the foundation's stated model of convening researchers, clinicians, pharmaceutical companies and patients reflects a broader shift towards privately organised science. Parkinson's is a progressive neurological disorder in which nerve cells producing dopamine become damaged or die, causing tremors, stiffness, slowed movement and difficulties with balance and coordination.
What is not yet known is how the reported $6 million compares with previous galas beyond the claim that it was a record, or how the foundation's figures on treatment approvals and funding totals have been independently audited. The claims about increased treatment options are attributed to the foundation itself, and the article gives no breakdown of where the $2.5 billion has gone or what proportion has produced approved therapies. Those details would matter to any assessment of the foundation's record, and they are not yet confirmed in the material available.
